REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

Operational Update

Landmark NMPA Approval of Senstend™, Marking a Transformational Milestone and Accelerating Commercialisation in China

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of Regent Pacific Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") in compliance with the disclosure requirements under Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is delighted to announce that the New Drug Application (the "**NDA**") for its innovative therapy, Senstend™, was approved by the National Medical Products Administration (the "**NMPA**"), inclusive of a 4-year data protection period on 10 June 2026 and notified to the Company after market hours on 15 June 2026.

This approval represents a major inflection point for the Company marking its successful transition into a commercial-stage biopharmaceutical leader. Senstend™ is indicated for the treatment of premature ejaculation, addressing a significant unmet medical need in the People's Republic of China ("**China**" or "**PRC**") and offers one of only two drugs now approved by the NMPA for the treatment of premature ejaculation, a compelling new therapeutic option for patients.

The Group expects to receive a total of US$7 million (or approximately HK$54.60 million) (before deduction of PRC withholding tax) in 2026 from two milestone payments from 江蘇萬邦生化醫藥集團有限責任公司 (Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.) ("**Wanbang Biopharmaceutical**", a wholly-controlled company of 上海復星醫藥（集團）股份有限公司(Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)) as the NDA approval triggers the payment of US$5 million (or approximately HK$39 million) (before deduction of PRC withholding tax) to the Group from Wanbang Biopharmaceutical.

Wanbang Biopharmaceutical anticipates commercial sales to commence in the second half of 2026 and this will trigger a payment of US$2 million (or approximately HK$15.60 million) (before deduction of PRC withholding tax) to the Group from Wanbang Biopharmaceutical. There are other significant payments payable to the Group from Wanbang Biopharmaceutical in respect of commercial milestones and royalties, amounting to:

- up to US$25 million (or approximately HK$195 million) in aggregate upon achievement of annual net sales after first commercial sales; and

- tiered percentage royalties on net sales, ranging from the low to mid-teens, except that lower payment structures will apply in certain circumstances where a generic product has successfully entered and impacted the market in China.

It is important to note that, under NMPA's trial data protection rules, Senstend™ is entitled to a 4-year data protection period. This means that, for 4 years after NMPA approval of Senstend™, unless the Group gives its consent, NMPA will not grant a marketing authorisation or supplementary application to another applicant (i.e. a generic or biosimilar competitor) that relies on the Group's self-obtained and undisclosed trial data or other data submitted to obtain approval.

Accordingly, during this data protection period, unless the Group gives its consent, generic or follow-on applicants who wish to obtain NMPA approval for a competing product of Senstend™ may only either: (i) obtain the data on its own and not rely on the Group's protected data (i.e. it does not stop a competitor from undertaking their own full, independent clinical trials from scratch); or (ii) wait until the 4-year data protection period expires.

Senstend™ has the potential to help about 9 million patients in China during its first year of launch, growing to over 170 million by the tenth year.

Jamie Gibson, the Chief Executive Officer of the Company, commented: *"This is a truly defining moment for the Company. The approval of Senstend™ by the NMPA underscores the strength of our scientific innovation, the quality of our clinical development, and our unwavering commitment to patients. We believe this milestone not only validates our commitment to the treatment of premature ejaculation but also positions us strongly for sustained growth and long-term value creation. Moving forward, the United States (the "**US**") is the logical next priority market for Fortacin™. Given the scale and attractiveness of the US addressable market, management is actively progressing the necessary workstreams with a view to finalising the regulatory approval pathway for Phase 3 clinical studies during 2026. We consider this to be a key strategic objective and an important potential catalyst in the Group's broader international growth trajectory."*

Senstend™ has demonstrated robust efficacy and a favourable safety profile with no adverse events in clinical studies, with results supporting its potential to become a best-in-class or first-in-class therapy in its category. The approval also highlights the Company's ability to successfully execute complex development and regulatory strategies across multiple jurisdictions.

The Group's commercial strategic partner, Wanbang Biopharmaceutical, is fully prepared for the commercial launch in China, with comprehensive plans in place covering manufacturing, supply chain, and market access. Wanbang Biopharmaceutical is actively advancing engagement with key stakeholders, including distributors and healthcare providers to support broad and timely patient access.

Strategic Commercial Partnership

The Company has established a strong strategic partnership with Wanbang Biopharmaceutical in China, which will be responsible for the marketing, distribution and sales of Senstend™ across the mainland China market.

Leveraging its extensive and well-established network, Wanbang Biopharmaceutical will drive commercialisation through multiple channels, including leading e-commerce platforms, hospital systems, clinics and other healthcare institutions. This integrated approach is expected to enable broad and efficient market penetration, ensuring that patients across China can access Senstend™ in a timely manner.

The Company believes that this partnership combines its innovative product capabilities with the partner's proven commercial infrastructure and market expertise, significantly enhancing the speed and scale of launch. The collaboration is expected to maximise the commercial potential of Senstend™ while supporting strong and sustainable revenue growth through the receipt of royalties and commercial milestone payments.

This asset-light commercialisation model allows the Company to focus on advancing its pipeline and core research and development capabilities, while benefiting from the partner's deep local market knowledge, established distribution channels and execution track record in China.

The Board believes that this approval will meaningfully enhance the Company's commercial outlook and shareholder value, reinforcing its position as a leading innovator in the biopharmaceutical sector.

Following the milestone NMPA approval of Senstend™, the Board believes the Group has entered an important new phase of development. Building on the experience, regulatory, commercial and strategic foundations established through Senstend™, the Board is actively evaluating a range of biopharmaceutical projects, licensing opportunities and strategic collaborations that could complement the Group's existing strategic direction, broaden the Group's pipeline, strengthen its long-term growth profile and enhance shareholder value.

About Senstend™

Senstend™ (the brand name for Fortacin™ in China) is a metered dose aerosol from a proprietary formulation of two marketed drugs, lidocaine and prilocaine, developed for treating premature ejaculation. The disorder affects approximately 20% to 30% of men in China, which translates to a significant initial target male population of approximately 55 million men aged between 20-59 years old, based on World Bank 2022 estimates rising to over 170 million men. In December 2018, Plethora Solutions Limited signed an exclusive license agreement with Wanbang Biopharmaceutical to market Senstend™ for premature ejaculation in China.

About the Company

The Company, a Hong Kong-listed biopharmaceutical company, is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders since its initial public offering in May 1997 (www.regentpac.com).

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US$ have been translated, for the purpose of illustration only, into HK$ using the exchange rate of US$1.00 = HK$7.80.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 16 June 2026

As at the date of this announcement, the Board comprises six Directors:

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi